Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2016

Published: May, 2016 | Pages: 85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's, 'Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2016', provides an overview of the Hanmi Pharmaceuticals, Co. Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Hanmi Pharmaceuticals, Co. Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Hanmi Pharmaceuticals, Co. Ltd.
- The report provides overview of Hanmi Pharmaceuticals, Co. Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Hanmi Pharmaceuticals, Co. Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Hanmi Pharmaceuticals, Co. Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Hanmi Pharmaceuticals, Co. Ltd.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hanmi Pharmaceuticals, Co. Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hanmi Pharmaceuticals, Co. Ltd.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hanmi Pharmaceuticals, Co. Ltd. Snapshot 9
Hanmi Pharmaceuticals, Co. Ltd. Overview 9
Key Information 9
Key Facts 9
Hanmi Pharmaceuticals, Co. Ltd. - Research and Development Overview 10
Key Therapeutic Areas 10
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Partnered Products/Combination Treatment Modalities 18
Pipeline Products - Out-Licensed Products 19
Out-Licensed Products/Combination Treatment Modalities 20
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products Glance 21
Hanmi Pharmaceuticals, Co. Ltd. - Late Stage Pipeline Products 21
Pre-Registration Products/Combination Treatment Modalities 21
Phase III Products/Combination Treatment Modalities 22
Hanmi Pharmaceuticals, Co. Ltd. - Clinical Stage Pipeline Products 23
Phase II Products/Combination Treatment Modalities 23
Phase I Products/Combination Treatment Modalities 24
Hanmi Pharmaceuticals, Co. Ltd. - Early Stage Pipeline Products 25
Preclinical Products/Combination Treatment Modalities 25
Discovery Products/Combination Treatment Modalities 26
Hanmi Pharmaceuticals, Co. Ltd. - Drug Profiles 27
HCP-1302 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
(HM30181A + paclitaxel) 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
eflapegrastim 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
HCP-1105 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
HCP-1303 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
HCP-1305 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
HCP-1401 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
HGP-0816 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
HGP-1207 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HIP-1402 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ALG-1001 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
efpegsomatropin 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
olmutinib 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
poziotinib 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
KX-01 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(HM30181A + irinotecan hydrochloride) 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
amlodipine besylate 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HCP-1202 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
HCP-1405 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HM-12525A 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
HM-71224 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
HM-95573 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BH-03004 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Biologics for Diabetes 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Biologics for Obesity 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecules 1 for Autoimmune Disorders 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules 2 for Autoimmune Disorders 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules for Acute Myeloid Leukemia 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules for Fibrosis and Oncology 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules for Oncology 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Biologics to Target CTLA4 and TNF Alpha 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Biologics to Target HER2 and CD3 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Biologics to Target HER2 and VEGFR 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HM-12260B 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules to Target ROR Gamma 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Analysis 65
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Target 65
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Route of Administration 67
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Molecule Type 68
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Mechanism of Action 69
Hanmi Pharmaceuticals, Co. Ltd. - Recent Pipeline Updates 71
Hanmi Pharmaceuticals, Co. Ltd. - Dormant Projects 82
Hanmi Pharmaceuticals, Co. Ltd. - Locations And Subsidiaries 83
Head Office 83
Other Locations & Subsidiaries 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List of Tables

Hanmi Pharmaceuticals, Co. Ltd., Key Information 9
Hanmi Pharmaceuticals, Co. Ltd., Key Facts 9
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Indication, 2016 11
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Stage of Development, 2016 14
Hanmi Pharmaceuticals, Co. Ltd. - Monotherapy Products in Pipeline, 2016 15
Hanmi Pharmaceuticals, Co. Ltd. - Combination Treatment Modalities in Pipeline, 2016 16
Hanmi Pharmaceuticals, Co. Ltd. - Partnered Products in Pipeline, 2016 17
Hanmi Pharmaceuticals, Co. Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 18
Hanmi Pharmaceuticals, Co. Ltd. - Out-Licensed Products in Pipeline, 2016 19
Hanmi Pharmaceuticals, Co. Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 20
Hanmi Pharmaceuticals, Co. Ltd. - Pre-Registration, 2016 21
Hanmi Pharmaceuticals, Co. Ltd. - Phase III, 2016 22
Hanmi Pharmaceuticals, Co. Ltd. - Phase II, 2016 23
Hanmi Pharmaceuticals, Co. Ltd. - Phase I, 2016 24
Hanmi Pharmaceuticals, Co. Ltd. - Preclinical, 2016 25
Hanmi Pharmaceuticals, Co. Ltd. - Discovery, 2016 26
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Target, 2016 65
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Route of Administration, 2016 67
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Molecule Type, 2016 68
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Mechanism of Action, 2016 70
Hanmi Pharmaceuticals, Co. Ltd. - Recent Pipeline Updates, 2016 71
Hanmi Pharmaceuticals, Co. Ltd. - Dormant Developmental Projects,2016 82
Hanmi Pharmaceuticals, Co. Ltd., Other Locations 83
Hanmi Pharmaceuticals, Co. Ltd., Subsidiaries 83